Jan. 09, 2025 (GLOBE NEWSWIRE ... Not to be confused with Vertex Pharmaceuticals, Vertex is a company specializing in consulting services and tax preparation software. S&P 500 components ...

Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE ... Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and precision medicine. With a market cap of $106.1 billion, Vertex ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...